CN104271576A - 激酶的吡啶并嘧啶酮抑制剂 - Google Patents

激酶的吡啶并嘧啶酮抑制剂 Download PDF

Info

Publication number
CN104271576A
CN104271576A CN201380021182.4A CN201380021182A CN104271576A CN 104271576 A CN104271576 A CN 104271576A CN 201380021182 A CN201380021182 A CN 201380021182A CN 104271576 A CN104271576 A CN 104271576A
Authority
CN
China
Prior art keywords
amino
pyrimidine
phenyl
alkyl
pyrido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380021182.4A
Other languages
English (en)
Chinese (zh)
Inventor
K.伍兹
A.马斯特拉基奥
赖春球
V.B.甘地
T.彭宁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of CN104271576A publication Critical patent/CN104271576A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201380021182.4A 2012-02-23 2013-02-22 激酶的吡啶并嘧啶酮抑制剂 Pending CN104271576A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261602163P 2012-02-23 2012-02-23
US61/602163 2012-02-23
PCT/US2013/027265 WO2013126656A1 (en) 2012-02-23 2013-02-22 Pyridopyrimidinone inhibitors of kinases

Publications (1)

Publication Number Publication Date
CN104271576A true CN104271576A (zh) 2015-01-07

Family

ID=47757712

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380021182.4A Pending CN104271576A (zh) 2012-02-23 2013-02-22 激酶的吡啶并嘧啶酮抑制剂

Country Status (8)

Country Link
US (1) US9718821B2 (enExample)
EP (1) EP2817308B1 (enExample)
JP (1) JP2015511245A (enExample)
CN (1) CN104271576A (enExample)
CA (1) CA2864142A1 (enExample)
ES (1) ES2606640T3 (enExample)
MX (1) MX2014010176A (enExample)
WO (1) WO2013126656A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105209463A (zh) * 2013-04-11 2015-12-30 阿尔麦克探索有限公司 2-氨基吡啶并[4,3-d]嘧啶-5-酮衍生物及其作为Wee-1抑制剂的用途
WO2019037678A1 (zh) * 2017-08-24 2019-02-28 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
WO2020063788A1 (zh) * 2018-09-27 2020-04-02 贝达药业股份有限公司 Fgfr4抑制剂及其应用
CN115397827A (zh) * 2020-03-27 2022-11-25 贝达药业股份有限公司 Fgfr4抑制剂的盐型、晶型及其用途

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201322602D0 (en) 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds
CN106459042B (zh) * 2014-04-02 2019-06-28 英特穆恩公司 抗纤维化吡啶酮类
CN106795154B (zh) * 2014-09-02 2019-07-05 皮埃尔法布雷医药公司 用于治疗癌症的异喹啉酮衍生物
GB201612095D0 (en) * 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds
JP6563623B1 (ja) * 2016-08-15 2019-08-21 ファイザー・インク ピリドピリミジノンｃｄｋ２／４／６阻害剤
US10954253B2 (en) 2017-01-23 2021-03-23 Shijiazhuang Sagacity New Drug Development Co., Ltd. 1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one derivative as Wee1 inhibitor
GB201703881D0 (en) * 2017-03-10 2017-04-26 Almac Discovery Ltd Pharmaceutical compounds
AU2018243667A1 (en) 2017-03-31 2019-10-17 Seagen Inc. Combinations of Chk1- and Wee1 - inhibitors
US20200291018A1 (en) * 2017-07-13 2020-09-17 Syros Pharmaceuticals, Inc. Tam kinase inhibitors
EP3694509A4 (en) 2017-10-09 2021-07-14 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND THEIR USES
EP3694861A4 (en) 2017-10-09 2021-05-19 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
AU2018361010B2 (en) 2017-11-01 2023-01-12 Wuxi Biocity Biopharmaceutics Co., Ltd. Macrocyclic compound serving as Wee1 inhibitor and applications thereof
GB201800378D0 (en) * 2018-01-10 2018-02-21 Almac Discovery Ltd Pharmaceutical compounds
EP3875460A4 (en) 2018-10-26 2022-07-20 Wuxi Biocity Biopharmaceutics Co., Ltd. PYRIMIDINDOPYRAZOLONE DERIVATIVE AS WEE1 INHIBITOR AND USE THEREOF
CN113874016A (zh) * 2019-01-29 2021-12-31 福宏治疗公司 化合物及其用途
JP2022528047A (ja) 2019-03-22 2022-06-08 ショウヤオ ホールディングス（ベイジン） カンパニー， リミテッド Ｗｅｅ１阻害剤、その製造および用途
JP2022526831A (ja) 2019-04-09 2022-05-26 ニューベイション・バイオ・インコーポレイテッド ヘテロ環式化合物およびその使用
HUE068061T2 (hu) 2019-04-30 2024-12-28 Wuxi Biocity Biopharmaceutics Co Ltd WEE1 inhibitor vegyület kristályos formája és felhasználása
WO2021155100A1 (en) 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
CA3180664A1 (en) 2020-06-17 2021-12-23 Yuli Xie Pyrazolo[3,4-d]pyrimidine-3-one derivative as wee-1 inhibitor
US12551584B1 (en) 2020-12-07 2026-02-17 Actinium Pharmaceuticals, Inc. Lewis Y radioimmunotherapy for the treatment of cancer
EP4332104A4 (en) 2021-04-30 2025-04-16 Wigen Biomedicine Technology (Shanghai) Co., Ltd. Fused ring compound as a WEE-1 inhibitor, as well as production process and use thereof
AU2022287033B2 (en) * 2021-06-04 2025-04-17 Aprea Therapeutics, Inc. Pyridopyrimidine derivatives useful as wee1 kinase inhibitors
CN116462687B (zh) 2022-01-18 2025-01-07 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途
MX2024010900A (es) 2022-03-07 2024-09-17 Debiopharm Int Sa Metodos para tratar el cancer de pulmon de celulas peque?as.
CN117402162A (zh) 2022-07-13 2024-01-16 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途
AR133820A1 (es) 2023-09-14 2025-11-05 Debiopharm Int Sa Combinación de un inhibidor de wee1 y un inhibidor de pkmyt1
WO2025133381A2 (en) 2023-12-22 2025-06-26 Debiopharm International S.A. Methods of treating solid tumors
WO2025186213A1 (en) 2024-03-04 2025-09-12 Debiopharm International S.A. Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633003A (en) * 1994-03-31 1997-05-27 Cantor; Jerome O. Use of intratracheally administered hyaluronic acid to ameliorate emphysema
YU66502A (sh) * 2000-03-06 2005-09-19 Warner-Lambert Company 5-alkilpirido(2,3-d)pirimidini, inhibitori tirozinkinaza
BRPI0510560A (pt) 2004-05-04 2007-11-20 Warner Lambert Co pirido[2,3-d] pirimidin-7-onas pirrolil substituìdas e seus derivados como agentes terapêuticos
ES2329419T3 (es) * 2006-01-31 2009-11-25 F. Hoffmann-La Roche Ag 7h-pirido(3,4-d)pirimidin-8-onas, su preparacion y uso como inhibidores de proteinas cinasas.
AR060635A1 (es) * 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
ES2432414T3 (es) 2008-08-12 2013-12-03 Glaxosmithkline Llc Compuestos químicos
AU2009321867B2 (en) * 2008-12-01 2015-12-10 Merck Patent Gmbh 2,5-Diamino-substituted pyrido[4,3-d]pyrimidines as autotaxin inhibitors against cancer
WO2010067888A1 (en) * 2008-12-12 2010-06-17 Banyu Pharmaceutical Co.,Ltd. Dihydropyrimidopyrimidine derivatives
ES2658290T3 (es) * 2009-10-29 2018-03-09 Genosco Inhibidores de cinasa
EP2882746B1 (en) * 2012-08-07 2016-12-07 Merck Patent GmbH Pyridopyrimidine derivatives as protein kinase inhibitors
GB201306610D0 (en) * 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105209463A (zh) * 2013-04-11 2015-12-30 阿尔麦克探索有限公司 2-氨基吡啶并[4,3-d]嘧啶-5-酮衍生物及其作为Wee-1抑制剂的用途
CN105209463B (zh) * 2013-04-11 2017-10-13 阿尔麦克探索有限公司 2‑氨基吡啶并[4,3‑d]嘧啶‑5‑酮衍生物及其作为Wee‑1抑制剂的用途
WO2019037678A1 (zh) * 2017-08-24 2019-02-28 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
CN109422754A (zh) * 2017-08-24 2019-03-05 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
WO2020063788A1 (zh) * 2018-09-27 2020-04-02 贝达药业股份有限公司 Fgfr4抑制剂及其应用
CN112771049A (zh) * 2018-09-27 2021-05-07 贝达药业股份有限公司 Fgfr4抑制剂及其应用
CN112771049B (zh) * 2018-09-27 2024-01-26 贝达药业股份有限公司 Fgfr4抑制剂及其应用
CN115397827A (zh) * 2020-03-27 2022-11-25 贝达药业股份有限公司 Fgfr4抑制剂的盐型、晶型及其用途
CN115397827B (zh) * 2020-03-27 2024-03-15 贝达药业股份有限公司 Fgfr4抑制剂的盐型、晶型及其用途

Also Published As

Publication number Publication date
JP2015511245A (ja) 2015-04-16
CA2864142A1 (en) 2013-08-29
ES2606640T3 (es) 2017-03-24
MX2014010176A (es) 2014-11-10
WO2013126656A1 (en) 2013-08-29
US20130225589A1 (en) 2013-08-29
EP2817308A1 (en) 2014-12-31
EP2817308B1 (en) 2016-09-07
US9718821B2 (en) 2017-08-01

Similar Documents

Publication Publication Date Title
ES2606640T3 (es) Inhibidores de cinasas de tipo piridopirimidinona
US8716297B2 (en) Chemical entities to be used for Wee1 inhibition for the treatment of cancer
US9181239B2 (en) Pyridopyrimidinone inhibitors of kinases
EP2560971B1 (en) Pyrrolopyridines as inhibitors of kinases
EP2558459B1 (en) Phthalazin-(2h)-one inhibitors of kinases
EP2558469B1 (en) Pyrrolopyrazinone inhibitors of kinases
CN103380117A (zh) 激酶的吡啶酰胺抑制剂
US9212192B2 (en) Bicyclic carboxamide inhibitors of kinases
CN103415516A (zh) Alk的双环抑制剂
CN103443102A (zh) 激酶的双环甲酰胺抑制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20150107

RJ01 Rejection of invention patent application after publication